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Abstract
Octreotide is approved as a one-month injectable for treatment of acromegaly and
neuroendocrine tumours. Oral delivery of the octapeptide is a challenge due mainly to low
intestinal epithelial permeability. The intestinal permeation enhancer (PE) salcaprozate
sodium (SNAC) has Generally Regarded As Safe (GRAS) status and is a component of an
approved oral peptide formulation. The purpose of the study was to examine the capacity of
salcaprozate sodium (SNAC), to increase its permeability across isolated rat intestinal
mucosae from five regions and across human colonic mucosae mounted in Ussing chambers.
Apical-side buffers were Kreb’s-Henseleit (KH), fasted simulated intestinal fluid (FaSSIFV2), rat simulated intestinal fluid (rSIF), and colonic simulated intestinal fluid (FaSSCoF).
The basal apparent permeability coefficient (Papp) of [3H]-octreotide was equally low across
rat intestinal regional mucosae in KH, rSIF, and FaSSIF-V2. Apical addition of 20 mM
SNAC increased the Papp across rat tissue in KH: colon (by 3.2-fold) > ileum (3.4-fold) >
upper jejunum (2.3-fold) > duodenum (1.4-fold) > stomach (1.4-fold). 20 mM and 40 mM
SNAC also increased the Papp by 1.5-fold and 2.1-fold respectively across human colonic
mucosae in KH. Transepithelial electrical resistance (TEER) values were reduced in the
presence in SNAC especially in colonic regions. LC-MS/MS analysis of permeated
unlabelled octreotide across human colonic mucosae in the presence of SNAC indicated that
[3H]-octreotide remained intact. No gross damage was caused to rat or human mucosae by
SNAC. Attenuation of the effects of SNAC was seen in rat jejunal mucosae incubated with
FaSSIF-V2 and rSIF, and also to some extent in human colonic mucosae using FaSSCoF,
suggesting interaction between SNAC with buffer components. In conclusion, SNAC showed
potential as an intestinal permeation enhancer for octreotide, but in vivo efficacy may be
attenuated by interactions with GI luminal fluid contents.
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1. Introduction
Acromegaly is a hormonal disorder that occurs due to the presence of a pituitary adenoma,
resulting in chronic overproduction of growth hormone. It is an orphan disease with an
annual prevalence of 30-60 cases/million people (Capatina and Wass, 2015). Treatment
includes surgery and therapeutic strategies to improve co-morbidities and quality of life (Lim
and Fleseriu, 2017). Peptides are highly potent and selective, and generate lower toxicity
compared to small molecules, making them attractive candidates for disease treatment (Lau
and Dunn, 2018). FDA-approved somatostatin peptide analogues for acromegaly include
octreotide and lanreotide. The octapeptide, octreotide (molecular weight (MW) 1019 Da) is a
first-generation synthetic analogue with a longer circulating t½ than native somatostatin
(Pless, 2005; Yang and Keating, 2010). Injectable formulations of octreotide have been
developed for acromegaly treatment over the last 30 years: Sandostatin® and Sandostatin®
LAR depot (Novartis, Geneva, Switzerland) (Fattah and Brayden, 2017). According to a
recent extensive survey however, a majority of patients with acromegaly stated that “an oral
therapy and/or a treatment to avoid injection” would be preferable to current injectable
analogues (Strasburger et al., 2016), whose administration is especially pain-inducing due to
use of low gauge needles. A once-daily oral formulation of octreotide would therefore be
attractive to patients and would improve compliance. The main challenges to address for oral
delivery of peptides, however, relates to their metabolic instability in the gastrointestinal (GI)
tract and very low permeability across intestinal epithelia (Brayden et al., 2020; Brown et al.,
2020; Drucker, 2020).
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Octreotide is cyclic and contains D-amino acids and a disulphide bridge, which confer some
stability against intestinal peptidases compared to typical linear peptide candidates (Wang et
al., 2015). Nonetheless, the hydrophilicity and high MW of octreotide result in low intestinal
epithelial permeability and this is the main reason for its low oral bioavailability. Some
delivery technologies have improved oral octreotide delivery in preclinical and clinical
studies (Fattah and Brayden, 2017). An oral octreotide formulation (Mycappsa®, Chiasma
Pharma, Jesusalem, Israel) uses Transient Permeability Enhancer™ (TPE™), developed by
Chiasma Pharma (Jerusalem, Israel), recently received the approval of the US FDA for an
octreotide capsule using Transient Permeation Enhancement™ technology for oral use in
acromegaly patients (Melmed et al., 2015; “MYCAPSSA,” 2020).
This technology involves formulating octreotide in an oily suspension with intestinal
permeation enhancers (PE). Briefly, the capsule consists of the medium chain fatty acid PE,
sodium caprylate (C8) and other excipients, combined with octreotide in an oily suspension,
which is then encapsulated in a pH-dependent polymeric enteric coating (Ben-Shlomo et al.,
2017). In rat intestinal instillation studies, C8 and the other excipients in TPE™ induced a
transient opening of small intestinal tight junctions, a likely basis for enhancing the
paracellular permeability of octreotide (Tuvia et al., 2014). Examination of the
pharmacokinetics of octreotide in the TPE™ formulation from a Phase I study indicated that
the oral bioavailability of Mycappsa™ was only ~0.25% (Tuvia et al., 2014). Co-formulation
of octreotide with other PEs has been investigated to some extent, but none of these studies e
progressed to clinical trials (Fricker et al., 1996; Fricker and Drewe, 1995; van der Merwe et
al., 2004). Overall, This would suggest that there is an opportunity to further increase the oral
bioavailability of octreotide using alternative formulations with more efficacious PEs than
C8.
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The 2019 FDA-approval of oral semaglutide (Rybelsus®, Novo Nordisk, Copenhagen,
Denmark) is likely to increase interest in oral formulations of other suitable peptide
candidates (Bucheit et al., 2019). Rybelsus® was the first glucagon-like peptide-1 (GLP-1)
receptor agonist to be approved by FDA for Type 2 diabetics by the oral route and it is
administered once-a-day. Even though its oral bioavailability in humans is 0.4 – 1.0%
(“RYBELSUS®,” 2020), this is still higher than Mycappsa®The non-enteric coated tablet
consists of either 7m or 14 mg semaglutide with the PE, 300 mg of salcaprozate sodium
(SNAC). SNAC prevents semaglutide degradation by pepsin through modifying the pH
around the tablet and by promoting permeability of monomeric semaglutide across the
stomach mucosa (Buckley et al., 2018). SNAC was discovered as a lead PE in the Eligen®
technology by Emisphere (Roseland, NJ, USA), whose researchers hypothesized that it could
chaperone poorly-permeable macromolecules across plasma membranes via a transcellular
mode of action (Park et al., 2011). Over the past 20 years, several other mechanisms of
action of SNAC were proposed on the basis that is it surfactant-like and is structurally
related to salicylic acid and medium chain fatty acids (Maher et al., 2019; Twarog et al.,
2019). From a regulatory standpoint, SNAC has generally regarded as safe status (GRAS)
and has also been marketed as an oral vitamin B12 supplement (Eligen®-vitamin B12,
Emisphere, USA) under Medical Food rules for several years (Castelli et al., 2011).
The main aim of this study was therefore to examine the potential of SNAC to promote
intestinal permeability of octreotide across rat and human tissue ex vivo. We investigated the
effects of SNAC on the apparent permeability coefficient (Papp) of [3H]-octreotide across
isolated rat intestinal tissue mucosae from five regions and from colonic human mucosae
mounted in Ussing chambers. A second aim was to develop a liquid chromatography-mass
spectrometry (LC-MS/MS) method for octreotide detection to provide evidence that there
was no radiolabel degradation during ex vivo fluxes of [3H]-octreotide. The third aim was to
5

assess the Papp of [3H]-octreotide in biorelevant simulated buffers bathing the apical sides of
isolated rat and human tissue mucosae in order to determine if potential components of
luminal fluids could interfere with SNAC performance. The results show that SNAC acts as a
PE for the peptide with increasing efficacy in rat intestinal mucosae in the proximal-distal
region direction as well as in human colonic mucosae in physiological Krebs-Henseleit (KH)
buffer. However, efficacy was attenuated in biorelevant buffers, suggesting that SNAC
performance in vivo may be over-predicted from standard Ussing chamber studies in KH
buffer.
2. Materials and Methods
2.1. Materials
Octreotide (> 95% purity) was purchased from ChinaPeptides Co., Ltd (Shanghai, China).
[3H]-octreotide (specific activity, 0.7 Ci/mmol) was obtained from Moravek, Inc. (Brea, CA,
USA). Ecoscint A, liquid scintillation cocktail, was from National Diagnostics (Atlanta, GA,
USA). Salcaprozate sodium (SNAC, MW 301 Da, > 99% purity) was obtained from
Shanghai Boc Chemicals Co., Ltd (Shanghai, China). Fasted State Simulated Intestinal FluidV2 (FaSSIF-V2) and Fasted State Simulated Colonic Fluid (FaSSCoF) were purchased from
Biorelevant.com Ltd (London, UK). All other reagents and chemicals were purchased from
Sigma-Aldrich (Arklow, Ireland).
2.2. Methods
2.2.1. Media
Composition of buffers are shown in Table 1. KH buffer was prepared in deionized H2O at
pH 7.4 with carbogen bubbling. Rat simulated intestinal fluid (rSIF) was prepared as
prescribed (Berghausen et al., 2016). It was prepared by dissolving sodium taurocholate,
sodium cholate hydrate, sodium chenodeoxycholic acid, and NaCl in 50 ml deionized H2O
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and stirred for approximately 30 min at room temperature. Lecithin, sodium oleate, and
glyceryl monooleate were added and the mixture was sonicated for 10 min and left stirred
overnight to yield a clear solution. Malenic acid and 40 ml deionized H2O were added and the
pH was adjusted to 6.0 with 1N NaOH. It was stirred until a clear solution was obtained and
finally the buffer volume was made up to 100 ml with deionized H2O. FaSSIF-V2 (pH 6.5)
and FaSSCoF (pH 7.8) were made up according to the manufacturer’s protocol (Biorelevant
Ltd). The buffers were used within 48 h of preparation and were stored at room temperature.
2.2.2. Preparation of dissected rat intestinal tissue for Ussing chamber studies
Male Wistar rats (250-300 g, from Charles River Staffron Walden, UK and the UCD
Biomedical Facility, Ireland) were used to study permeability. Rats were housed and used
according to the National Institute of Health directive: “Principle of Laboratory Animal Care”
(NIH publication number 85-23, 1985). Approval of this project was granted by the UCD
Research Ethics Committee for animal experimentation (AREC approval number 14-28Brayden). Rats were euthanized by stunning and cervical dislocation. After laparotomy,
resected duodenum (up to 10 cm from pylorus), upper jejunum (< 11 cm from pylorus), ileum
(up to 10 cm above the caecum) and colon were placed in carbogenated KH buffer and
dissected according to previous descriptions (Cuthbert and Margolius, 1982). Musclestripped stomach mucosae was prepared by a blistering technique (Hopkins et al., 2002).
Dissected tissues were mounted between two halves of chambers and maintained in 5 ml
temperature-controlled carbogenated KH buffer on each side and with an exposed window
area of 0.63 cm2. Baseline potential difference (PD, mV) and short circuit current (Isc,
µA.cm-2) were measured using a DVC 4000 Voltage Clamp (WPI, Hichin, UK) by using a
PRO-4 timer (WPI) to switch between open circuit- and voltage clamping to zero,
respectively. Transepithelial electrical resistance, TEER (Ω.cm2) was calculated by Ohm’s
Law (Equation 1).
7

⁄
Tissues from stomach, duodenum, jejunum, and ileum with minimum TEER values > 30
Ω.cm2 and colonic mucosae with minimum TEER values > 70 Ω.cm2 were used for
permeability studies (Petersen et al., 2012; Ungell et al., 1998). Analogue data was digitised
with a Powerlab® data acquisition unit and analyzed with Chart® software package (AD
Instruments, UK).
2.2.3. Preparation of dissected human colonic mucosae for Ussing chamber studies
Human colonic specimens were sourced from surgical colon resections. Ethical approval for
this study (Protocol 190/2012) was obtained from the St. Vincent's University Hospital
Institutional Review Board, and it included informed patient consent. Resections were
obtained from patients with suspected colorectal carcinoma. After resection, fresh normal
human colonic tissue specimens were obtained from above the diseased margin as designated
by a pathologist. Specimens were incubated in ice-cold phosphate buffered saline (PBS).
When the tissue arrived at laboratory within 60 min of excision, it was transferred into fresh
carbogenated ice-cold KH buffer and kept on ice. Subsequently, the tissue was transferred to
a dissection bowl containing carbogenated ice-cold KH buffer (Figure 1). The tissue was
pinned with the luminal side down on a dissection board. The circular and longitudinal
smooth muscle of human colonic tissue was dissected from the basolateral side of mucosae
(Kisser et al., 2017) using size 5 watchmaker forceps. Stripped mucosae were mounted in
pre-equilibrated Ussing chambers (WPI) as described above within 2-3 h of resection.
Mucosae with minimum TEER values > 70 Ω.cm2 were used for permeability studies (Maher
et al., 2009).
2.2.4. Fluxes of octreotide across isolated rat and human intestinal mucosae
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The apparent permeability (Papp) values of either [3H]-octreotide (0.5μCi/ml) or unlabelled
octreotide (10μM) were assessed across intestinal tissues from rat and human in the presence
of SNAC. [3H]-octreotide and octreotide with or without SNAC (20 mM and 40 mM) were
added to the apical compartment bathing mucosae and 0.2 ml samples were taken from
basolateral compartment every 20 min over 120 min. Each basolateral sample was replaced
an equal volume of KH buffer. Some studies were also carried out in the presence of
biorelevant media, rSIF, FaSSIF-V2, and FaSSCoF, which were added to apical compartment
only, with KH retained on the basolateral side otherwise. These investigations were carried
out in order to better model in vivo GI conditions that may affect drug and PE solubility and
permeability. Human FaSSIF-V2 is now being widely used by researchers to incubate
isolated rat intestinal mucosae in order to determine permeability and solubility in biorelevant
buffers (Berghausen et al., 2016; Forner et al., 2017; Wuyts et al., 2015). Given that the bile
salt concentrations are 3 mM in FaSSIF-V2 and 25 mM in rSIF, differences in in vitro
permeability of octreotide might be expected as bile salts are also recognised as efficacious
PEs (Berghausen et al., 2016; Brown et al., 2020). Therefore, we used both rSIF (to mimic rat
luminal contents in vivo), as well as FaSSIF-V2 (to model those of the human small
intestine). Previous studies demonstrated compatibility between rat isolated small intestinal
tissue mucosae using FaSSIF-V2 in the apical compartment of Ussing chambers (Forner et
al., 2017; Wuyts et al., 2015). Fed-state simulated intestinal fluid (FeSSIF) was not used as it
is too damaging to isolated rat jejunal mucosa (Kristin et al., 2017) and could give rise to
false-positive flux data.
The fluxed samples of [3H]-octreotide were mixed with 3 ml liquid scintillation cocktail
(Ecoscint A), and radioactivity was quantified using a liquid scintillation counter (Packard
Tricab 2900 TR, PerkinElmer, Massachusetts, USA).
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Unlabelled octreotide samples were quantified using LC-MS/MS. These samples were mixed
with chilled MS grade acetonitrile and stored at -20°C until analysis. Thawed samples were
centrifuged at 15,000 rpm at 4°C and analysed. The LC-MS/MS system consisted of a triple
quadrupole mass spectrometer coupled to a UHPLC system (6470 Triple Quad LC/MS
(Model G6470A) Agilent Technologies, California, USA). An AdvanceBio Peptide Map
column (2.7 µm, 150 x 2.1 mm) (Agilent Technologies) was used. The injection volume was
2 µl. The chromatographic conditions were: 400 µl/min flow rate for 10 min, with the mobile
phase consisting of (A) 0.1% formic acid and (B) acetonitrile. The gradient A:B (v/v) was
programmed as follows: from 0 to 4 min the ratio of A:B 90:10 to 20:80 which was
maintained for 1 min. The column was re-equilibrated for the next 5 min with the initial ratio
of mobile phase. The transition from m/z 510.3 to m/z 120.1 was used to quantify octreotide,
with analysis was done using a multiple reaction monitoring (MRM) model. MRM
parameters are from Ismaiel et al., (Ismaiel et al., 2011) with slight modification: Dwell time
200 ms, collision energy 48, Cell Accelerator Voltage 5 and Fragmentor 5. The Papp values of
[3H]-octreotide and octreotide were calculated according to the following Equation 2:
⁄

⁄

where dQ/dt was the transport rate across the epithelium (mol/s), A was the surface area of
the cell monolayer (0.63 cm2), and C0 was the initial concentration of [3H]-octreotide or
octreotide in the apical donor compartment (mol.ml-1) (Kisser et al., 2017).
2.2.5. Histology of tissue mucosae
Following the 2 h permeability experiments, rat and human tissues were removed from the
chambers and fixed in 10% w/v buffered formalin for histology to evaluate potential
epithelial damage. After 24 h, the tissues were embedded in paraffin wax. Tissue sections of
5 µm thickness were cut with a microtome (Leitz 1512; GMI, Minnesota, USA) and stained
10

with haemotoxylin/eosin (H & E) and examined with a light microscope (BX43, Olympus,
Tokyo, Japan).
2.3. Statistical analysis
Statistical analysis was carried out using Prism-8® software (GraphPad, San Diego, USA).
Results are given as mean ± standard error of mean (SEM). Student’s t-tests (unpaired) and
ANOVA were used for group comparisons with post hoc tests used for the latter. Statistical
significance was considered present if p < 0.05.
3. Results
3.1. SNAC increases the Papp of [3H]-octreotide across rat intestinal mucosae in KH
The effects of 20 mM SNAC in KH buffer were examined on the Papp of [3H]-octreotide
across rat intestinal mucosae isolated from five regions: stomach, duodenum, upper jejunum,
ileum, and colon. The basal Papp of [3H]-octreotide ranged from 1.3 x 10-6 cm.s-1 to 2.5 x 10-6
cm.s-1 across mucosae from each region, but they were not different from each other (Figure
2A). The SNAC concentration was below its critical micellar concentration of 36 mM in KH
buffer (Suppl. Figure 1). In stomach mucosae, apical addition of SNAC increased the Papp to a
small extent from 1.3 x 10-6 cm.s-1 to 1.9 x 10-6 cm.s-1. In the presence of SNAC, the Papp
across duodenal mucosae was also marginally increased in the presence of SNAC from 2.1 x
10-6 cm.s-1 to 3.0 x 10-6 cm.s-1, but neither trend was significant. Statistical increases in the
Papp were however, observed in upper jejunal, ileal, and colonic mucosae: from basal values of
1.9 x 10-6 cm.s-1 to 4.2 x 10-6 cm.s-1, from 2.2 x 10-6 cm.s-1 (basal) to 7.4 x 10-6 cm.s-1, and
from 2.5 x 10-6 cm.s-1 (basal) to 7.9 x 10-6 cm.s-1, respectively (Figure 2A). There was
therefore a pattern indicating increasing efficacy of 20 mM SNAC in KH buffer in the order
of stomach < duodenum < jejunum < ileum < colon (Figure 2A). These results indicate
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regional effects of SNAC as a PE for this peptide in rat intestinal tissue with increasing
efficacy observed in the proximal-to-distal direction.
TEER values in the presence of [3H]-octreotide gradually declined to ~40% of the initial
TEER over 120 min in tissues from the different GI regions from rats (Figure 2B-F). These
changes in TEER were similar to patterns observed in untreated rat intestinal mucosae
(Stuettgen and Brayden, 2020; Twarog, 2020), so there was no indication that [3H]-octreotide
itself might be causing TEER reductions across mucosae from the five regions. Following
apical addition of 20 mM SNAC however, TEER values were further reduced across four of
the regions compared to [3H]-octreotide-exposed controls, except for duodenal mucosae. The
times required for significant reductions in TEER when exposed to SNAC compared to the
respective tissue controls ([3H]-octreotide alone) were: stomach from 20 - 120 min (20% 40% reduction), jejunum at 120 min (35% reduction), ileum from 80 - 120 min (30% - 38%
reduction), and colon from 15 -120 min (44% - 83% reduction) (Figure 2B-F).
3.2. No effects of SNAC on the Papp of [3H]-octreotide across rat jejunal mucosae in
rSIF or FaSSIF-V2
We further investigated the permeability of [3H]-octreotide across rat intestinal tissue
mucosae by replacing KH buffer on the apical side with simulated intestinal fluids as
indicated in section 2.2.4.
Since 20 mM SNAC induced a significant increase in the Papp of [3H]-octreotide across rat
upper jejunal mucosae in KH buffer, we re-examined whether this effect pertained in tissues
just from this region in the presence of rSIF and FaSSIF-V2 on the apical side. The basal Papp
for [3H]-octreotide across jejunal mucosae in rSIF and FaSSIF-V2 was 1.6 x 10-6 cm.s-1 and
1.7 x 10-6 cm.s-1, respectively, unchanged from that obtained in KH buffer (1.9 x 10-6 cm.s-1).
However, attenuation of the permeation-enhancement effects of SNAC in KH buffer was
12

observed in both rSIF and FaSSIF-V2. The Papp of [3H]-octreotide in the presence of 20 mM
SNAC in rSIF and FaSSIF-V2 was 1.2 x 10-6 cm.s-1 and 1.9 x 10-6 cm.s-1, respectively, not
different from the control Papp in these buffers. Yet these values were both lower than the Papp
value detected in presence of SNAC in KH buffer, (4.2 x 10-6 cm.s-1) (p < 0.05) (Figure 3A).
Since the critical micellar concentration (CMC) of SNAC in rSIF and FaSSIF-V2 was
lowered to 5.6 mM and 6.3 mM, respectively, an explanation is that the free concentration
was of SNAC was reduced in these buffers due to mixed micelles forming in the presence of
NaTC and lecithin contributions (Suppl. Figure 1).
There was a trend of a slight gradual reduction in TEER values over 2 h in control tissues
exposed to [3H]-octreotide in rSIF and FaSSIF-V2 buffers. In turn, these reductions were
similar to the gradual pattern for TEER reduction seen in KH buffer, indicating compatibility
of jejunal tissue with these biorelevant media over this period (Figure 3B). This result
indicated compatibility of these two simulated small intestinal buffers with isolated intestinal
tissue mounted in Ussing chambers (Forner et al., 2017; Jantratid et al., 2008; Wuyts et al.,
2015). 20 mM SNAC did not cause additional TEER reductions in jejunal tissue in either
simulated buffers, in contrast to additional reductions observed in the presence of SNAC in
KH.
3.3. SNAC increases the Papp of octreotide across human colonic mucosae in KH buffer
Due to difficulty in accessing sufficient human specimens from different GI regions, we were
limited to investigating effects of SNAC on the Papp of [3H]-octreotide in human colonic
mucosae, where surgeries to obtain tissue are common. Following apical addition of SNAC
(20 mM and 40 mM) in KH buffer, the Papp increased by 1.5-fold to 1.9 x 10-6 cm.s-1 (NS)
and by 2.1-fold to 2.7 x 10-6 cm.s-1 (p = 0.03) respectively, compared to the control Papp of 1.3
x 10-6 cm.s-1 (Figure 4A) for [3H]-octreotide alone. Therefore, 40 mM SNAC was required to
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statistically achieve same effect in human colonic mucosae as seen for the rat counterpart (20
mM).
We developed an LC-MS/MS method to quantify unlabelled octreotide on the basolateral
side in order to confirm the data seen with [3H]-octreotide in KH buffer and to show that
measurement of the radiolabel did not reflect metabolism of the link between tritium and
octreotide during transit. Following addition of 40 mM SNAC, the Papp of unlabelled
octreotide increased to 2.3 x 10-6 cm.s-1 compared the control basal Papp of 6.2 x 10-7 cm.s-1,
although this trend was not quite significant (p= 0.23) (Figure 4C). The Papp values for
labelled and unlabelled octreotide were therefore of the same order, indicating that both sets
of values were a true measure of intact peptide flux. Had tritium split from octreotide, the P app
for tritium would have been orders of magnitude higher, ~0.68 x 10-4 cm.s-1 (Twarog, 2020).
The effect of SNAC on the TEER of human colonic mucosae was investigated. The mean
basal TEER was 99.6 ± 9.5 Ω.cm2 (n=24), similar to values reported by others (Maher et al.,
2009; Petersen et al., 2012). Following 120 min incubation, the mean TEER of control tissues
exposed to [3H]-octreotide gradually decreased by a small amount, ~25% (Figure 4B),
similar to control tissues in the absence of [3H]-octreotide, so there was no indication that
[3H]-octreotide reduced TEER in human colonic mucosae per se. Upon apical addition of
either 20 mM or 40 mM SNAC, there was additional reduction in TEER compared to
controls (Figure 4B and C).
3.4. Attenuated effects of SNAC on the Papp of octreotide across human colonic
mucosae in FaSSCoF
In an attempt to better mimic the in vivo situation where the luminal side of intestinal fluid is
exposed to bile salts and lecithin, we used a simulated human colonic buffer on the apical
side of human colonic tissue. FaSSIF-V2 is considered suitable for the upper small intestinal
14

region (Forner et al., 2017; Jantratid et al., 2008), so we tested the effects of SNAC on the
Papp of [3H]-octreotide using a human colonic version, FaSSCoF. The Papp of [3H]-octreotide
in FaSSCoF increased by 1.7-fold from 1.5 x 10-6 cm.s-1 (mean basal) to 2.6 x 10-6 cm.s-1, and
by 1.9-fold to 2.8 x 10-6 cm.s-1 in the presence of 20 mM and 40 mM SNAC, respectively, but
statistical significance was not reached (Figure 5A). TEER values of control tissues exposed
to [3H]-octreotide in FaSSCoF were unchanged over 2 h, whereas in the presence of SNAC
(20 mM, 40 mM), TEER values decreased further (Figure 5B).
3.5. Minor changes in intestinal mucosae morphology in the presence of SNAC in KH
Histology of rat and human tissue mucosae following exposure to SNAC over 120 min was
assessed (Figure 6A and B). Rat stomach mucosae exposed to KH buffer and 20 mM SNAC
were structurally intact with just minor perturbation observed (Figure 6A). In rat duodenal
and jejunal mucosae, minor cell sloughing at the tip of villi was seen in control and SNACexposed tissues. More sloughing was noticeable in rat ileal and colonic mucosae where the
tips of villi were absent following exposure to SNAC (Figure 6A). As seen in Figure 6B,
human colonic mucosae in KH buffer appeared structurally intact with healthy villi present,
similar to that of control tissue. Human tissues exposed to 20 mM SNAC showed minor
damage to villi tips, whereas 40 mM SNAC caused tip erosion.
Discussion
PEs have potential to increase the bioavailability of poorly permeable drugs and
macromolecules (Maher et al., 2019, 2016). The approval of Rybelsus® (oral semaglutide) for
the treatment of Type 2 diabetes is rightly considered a landmark for oral peptide delivery
and offers encouragement to use PE-containing formulations to be used for other peptides
even though the oral bioavailability is ~1% (“Rybelsus® (oral semaglutide),” 2020). Upon
closer scrutiny however, rather than opening up the oral peptide field for use with PE
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formulations, it restricts it to niche peptides as only highly potent peptides of reasonable MW,
with acceptable stability, a long t½, and a large therapeutic index can be considered as
candidates at that low and variable level of bioavailability. Perhaps such candidates will
emerge through the efforts of medicinal chemistry, which is focussed on producing
membrane-permeable stable macrocycles of lower MW than typical linear peptides (Naylor
et al., 2017). For this study, we selected octreotide because it displays several of those
promising features, although its stability in the GI tract is still relatively low despite its cyclic
structure (Wang et al., 2015). Moreover, an oily suspension largely based on the PE, C8, was
recently approved by the FDA despite an oral bioavailability of ~0.25%, so there is potential
to further improve its systemic delivery. We paired octreotide with SNAC as a wellestablished PE, present in Rybelsus® at a daily level of 300 mg per dose. It is not necessarily
the most efficacious PE (that is typically pay-load dependent), but it has an excellent safety
record, GRAS status, and can be produced to Good Manufacturing Practice (GMP) quality in
large quantities. SNAC is already on the market as a component of an oral semaglutide
formulation (Rybelsus®) since 2019..
Here, we demonstrated that SNAC is efficacious at increasing octreotide flux across isolated
rat and human intestinal mucosae in the standard KH physiological buffer used for ion
transport and drug flux studies across epithelial mucosae mounted in Ussing chambers. This
was not a particular surprise as SNAC is well-known to have capacity to increase oral
absorption of several co-administered poorly permeable molecules apart from semaglutide
including unfractionated heparin, cromolyn, and vitamin B12 (Leone-Bay et al., 1998, 1996;
Smith et al., 2016). Yet, exact mechanism of action remains controversial, recently it has
been provided a specific mechanism for SNAC in respect of close association with
semaglutide in a tablet in the stomach, based on buffering against acid, protection against
pepsin, and presentation of semaglutide to the gastric epithelium as a monomer (Buckley et
16

al., 2018). In that study, it was suggested that neither replacing semaglutide with another
GLP-1 analogue, liraglutide, nor replacing SNAC with another Eligen™ PE analogue
sufficed to increase flux across gastric epithelial monolayers. The gastric mechanism of
action of SNAC in respect of semaglutide that was demonstrated in ligated dogs does not,
however, rule out SNAC effects in other GI regions with other payloads where it can exert
membrane perturbation due to its surfactant structure and capacity to alter a range of
epithelial intracellular parameters (Twarog, 2020).
The basal Papp was low and equivalent for [3H]-octreotide across all five regions, as expected
for a hydrophilic peptide of MW ~1000 Da. Similarly, Forner et al., also showed that the Papp
of FITC-labelled dextran 4000 (FD4) was constant across different rat intestinal regional
mucosae (Forner et al., 2017). Peterson et al., on the other hand demonstrated regional
differences in the basal Papp of [14C]-mannitol and FD4, with higher permeability observed in
isolated rat jejunal- than colonic mucosae (Petersen et al., 2012). In the current study and that
of Forner et al., the upper jejunal region was used while in Petersen et al., the distal jejunum
was used instead. These two jejunal regions may have different basal permeabilities. In
addition, while mannitol and FD4 fluxes are mediated by the paracellular pathway, octreotide
flux can be mediated by both transcellular and paracellular pathways (Fricker et al., 1992,
1991), another possible source of variation.
SNAC’s effects were regional-dependent in rat tissue in KH buffer, with greater efficacy as a
PE at increasing the Papp of [3H]-octreotide in the proximal-to-distal direction. To our
knowledge, this is the first study to systematically evaluate regional differences of SNAC as a
PE for octreotide across rat intestinal mucosae. A recent presentation from Merck (NJ, USA)
also investigated the capacity of SNAC to increase flux of octreotide across isolated rat
intestinal mucosae mounted in diffusion chambers (“Novel Approaches for Enhancing the
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Oral Bioavailability & Absorption of Peptides,” 2020). Flux was increased by 4.8% w/v
SNAC, equivalent to 66 mM, more than a 3-fold higher concentration than used here. No
histology was presented in the Merck study and the intestinal region was not stated.
Nonetheless, it corroborates some of the findings of this project. In the current study,
SNAC’s efficacy as a PE was weakest in stomach mucosae for this payload. In Buckley et
al., rat gastric mucosae were mounted in chambers and exposed to 10-30 mM SNAC. Their
results showed an increase in permeability of semaglutide during an acute 10 min exposure to
SNAC followed by removal of the PE-containing buffer, with efficacy gradually declining at
30 and 60 min (Buckley et al., 2018). In our study, the gastric mucosa was exposed
chronically to 20 mM SNAC over 2 h, so constant exposure to SNAC in this design would
favour a sustained effect on the epithelium, even if acute exposure is a more likely scenario in
vivo (Buckley et al., 2018). Irrespective, there is no doubt that the efficacy of SNAC as a PE
on rat stomach mucosae is markedly different between these studies: this could be down to
differences in stomach dissection technique, or that SNAC is simply more efficacious with
semaglutide than with octreotide in stomach mucosa. Taken together, since the stomach
appears less amenable to PEs than regions lower down the GI tract, the gastric mode of action
for SNAC in the oral formulation of semaglutide is likely to be built primarily upon pHbuffering and monomer induction rather than relying on stomach permeation-enhancement.
Small intestinal regional absorption has in fact been demonstrated before for octreotide.
Fricker et al., showed higher uptake of octreotide from jejunum than ileum from humans and
rats (Fricker et al., 1992, 1991). Despite efficacy observed for SNAC in respect of the P app of
[3H]-octreotide in rat distal intestinal mucosae in the current study, it still took a
concentration of 20 mM to achieve it, reflecting its low potency. This is consistent with a
requirement for 300 mg in the oral semaglutide tablet, a weight ratio of 21:1 (SNAC :
peptide).
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Targeting and releasing drug contents in the colonic region has been advocated for
formulations that act locally (Bak et al., 2018). Compared to the small intestine, the colon has
a lower surface area compensated by a longer transit time (20-30 h), which permits a longer
time to release the material (Jones et al., 2016). The observation of increased efficacy of
SNAC in lower GI intestinal mucosae is in line with other studies of PEs with isolated rat
intestinal mucosae (Maroni et al., 2012; Petersen et al., 2012; Yamamoto et al., 1997). The
PE, sodium caprate (C10), also demonstrated superior efficacy in isolated rat colonic mucosae
compared to jejunal in respect of promoting flux of macromolecule (Maroni et al., 2012;
Petersen et al., 2012; Yamamoto et al., 1997). Recently, our group also showed efficacy of
another PE class, piperazine derivatives, on increasing the Papp of [3H]-octreotide across rat
colonic mucosae (Stuettgen and Brayden, 2020). It is not known why the colon seems to be
especially amenable to many PEs, but it is possible that the plasma membrane lipid
composition of colonic enterocytes may be different from the small intestine. A more likely
explanation is that the small intestine has adapted to coping with up to 20 mM bile salts in the
fed state along with challenges from nutrients, so that it should be more resilient seems
intuitive. Even if the colon is arguably the most amenable site for PE to act, it is still not a
very attractive option for the systemic delivery of peptides due to the variable GI transit time
to reach there with coated oral dosage forms and also due to the complexity of the colonmicrobiome interaction (Bak et al., 2018). The histological observations of just mild
perturbation observed with SNAC in mucosae from different GI regions from rats are in line
with effects of other surfactant-type PEs (Maher et al., 2018; McCartney et al., 2019;
Stuettgen and Brayden, 2020).
The basal Papp values of [3H]-octreotide across rat jejunal and human colonic mucosae were
not altered in the biorelevant buffers compared to KH buffer. Forner et al., also observed
similar Papp values for FD4 and atenolol in HBSS versus modified FaSSIF on the apical side
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of isolated rat jejunal mucosae (Forner et al., 2017). Attenuation of the efficacy of SNAC was
however seen here in FaSSIF-V2 and rSIF, and to lesser extent with FaSSCoF. The lack of
effect of SNAC on the Papp of [3H]-octreotide seen in these buffers is likely to be due to
interaction of SNAC with components of simulated fluids since basal fluxes were unchanged.
Several factors might contribute to the attenuation of SNAC’s effects in the simulated fluids.
The initial study showing efficacy of SNAC was carried out in rat and human intestinal tissue
in KH buffer at pH 7.4, whereas both FaSSIF-V2 and rSIF were used at pH < 6.5. Even with
even a small change in pH, different dissolution profiles can be obtained (Berben et al., 2019;
Falavigna et al., 2019). A difference in pH might affect the solubility of SNAC (Cumming
and Martin, 2000). SNAC is the sodium salt of a weak acid with a pKa of 5.01. At low pH,
the solubility of SNAC decreases and the SNAC precipitates as the SNAC free acid form
(Cumming and Martin, 2000). Changes in pH could also alter the degree of ionization of
octreotide, but this does not seem relevant, otherwise a decrease in the basal Papp would have
been detected. It is also possible that a change in pH could affect the interaction between
SNAC and octreotide. A decrease in pH can also alter rheology of mucus, which might
increase the barrier for the peptide or PE to reach the epithelium (Berben et al., 2019;
Falavigna et al., 2019).
SNAC might also be entrapped in micelles by key components of biorelevant fluids, bile salts
and lecithin, thereby reducing its free concentration. Both sodium taurocholate (NaTC) and
lecithin form colloidal structures in simulated intestinal fluids, while FaSSIF consists of
mixed-micelles of different sizes (40-100 nm). Gradauer and colleagues also saw similar
attenuation in efficacy of the non-ionic surfactant PE, tetradecyl maltoside (Gradauer et al.,
2015). In that study, the enhancement capacity of the maltoside to increase permeability of
FD4 was reduced in FaSSIF-V2 across Caco-2 monolayers and in rat intestinal instillations.
The authors provided evidence for entrapment of the maltoside at concentrations above its
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CMC in mixed micelles comprising NaTC/lecithin. Whether this occurs for SNAC is unclear
as its CMC in KH buffer is 36 mM, above the 20 mM concentration that proved efficacious
in rat tissue, but lower than the 40 mM concentration required for human colonic mucosae.
However, the CMC of SNAC in rSIF and FaSSIF was 5.6 mM and 6.3 mM, respectively, so
it is likely that mixed micelles form in these buffers that lead to reduction in its free
concentration, thereby providing a plausible explanation for the lack of effect.
Evaluation of permeability and PE effects using simulated colonic fluid with human mucosa
on Ussing chambers has to our knowledge never been conducted before. To date, only
dissolution of molecules has been determined in this new buffer, so it needs verification to
confirm its suitability for predicting permeability in human colonic mucosae (Augustijns et
al., 2014; Vertzoni et al., 2019, 2010). However, incubating human colonic mucosae in KH
buffer is well-established and yields correlation with fraction absorbed across human colon in
vivo (Lennernäs, 2007). The Ussing chamber was originally designed for epithelial
electrophysiology, with TEER measurement used to monitor electrical leakiness of tight
junctions, as well as the integrity of the mounted tissues. Reduction in TEER is not an
indication of toxicity or paracellular mode of action, as transcellular perturbation can also
reduce TEER (Maher et al., 2019). Hess et al., demonstrated that SNAC (33-66 mM) could
increase the permeability of polar marker molecule, 6-carboxy-fluorescein in isolated rat
jejunal mucosae, surprisingly without reducing TEER values at such high concentrations
(Hess et al., 2005). Thus, the reduction in TEER induced by SNAC in the mucosae of the
current study reveals very little on electrophysiology changes, permeability pathways, or the
mechanism of action. It is more likely to simply reflect the mild perturbation seen in the
histology images.
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In conclusion, the effect of SNAC as a PE for octreotide permeability across in human and rat
intestinal membrane was evaluated. Regional differences were found for the SNAC
enhancement effect with the best efficacy seen in rat colon, which was confirmed for human
colon. Moreover, the influence of rSIF and FaSSIF-V2 on the permeability of octreotide in
presence of SNAC was investigated which resulted in attenuation of the PE effect, likely
related to entrapment in micellar components of simulated fluid containing NaTC and
lecithin, leading to a reduction in the free concentration that can access the plasma
membrane. Finally, our results showed compatibility of simulated fluids mapped to intestinal
regional mucosae in Ussing chambers. Use of biorelevant compatible buffers for ex vivo
fluxes which mimic the lumen contents of intestinal regions have the potential to offer more
complex mechanistic insights for how PEs act and more accurate predictions of in vivo
outcomes. Whether SNAC can be formulated in tablets with octreotide to compete with the
very low oral bioavailability in humans offered by TPE™ will require initial assessment in
large animal studies.
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Table 1. Buffer compositions on the apical side of rat and human intestinal mucosae in
Ussing chambers

KH

rSIF

FaSSIF-V2

FaSSCoF *

118 mM NaCl

18.7 mM NaCl

68.6 mM NaCl

0.15 mM sodium
cholate

5 mM sodium
taurocholate
12.5 mM sodium
cholate hydrate
7.5 mM sodium
chenodeoxycholic acid

3 mM sodium
taurocholate

0.3 mM Lecithin

0.2 mM Lecithin

0.1 mM sodium oleate

19.1 mM malenic

45.4 mM Tris

34.8 mM sodium
hydroxide

120 mM sodium
hydroxide

4.7 mM KCl
2.5 mM CaCl2
1.2 mM MgSO4
1.2 mM KH2PO4

5.2 mM Lecithin

25 mM NaHCO3

0.3 mM sodium oleate

11.1 mM glucose

1.7 mM glyceryl
monooleate
29.9 mM malenic

* human colonic mucosae studies only. In all studies KH was used on the basolateral side.
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Figure legends:
Figure 1. Representative images of dissected human colonic mucosae for Ussing system. (A)
Human colonic specimen, (B) Colonic tissue after removing smooth muscle; the luminal side
is faced down on the dissection board, (C) Muscle-stripped mucosae mounted tissue on an
Ussing chamber. Horizontal bars = 35 mm.

Figure 2. Papp of [3H]-octreotide and TEER across rat intestinal regional mucosae. A. Papp of
[3H]-octreotide in absence and presence of 20 mM SNAC in KH buffer, * P < 0.05, (Student’s
unpaired t-test) comparing Papp in the presence of SNAC against regional controls exposed to
[3H]-octreotide alone. B-F. Percentile of initial TEER in tissues exposed either to [3H]octreotide alone or to SNAC and [3H]-octreotide. B. Stomach, C. Duodenum D. Jejunum, E.
Ileum, F. Colon.

*

P < 0.05, two-way ANOVA followed by Bonferroni post hoc analysis

comparing TEER values within regions. Data expressed as Mean ± SEM (n= 6-7 per group).
The dotted line indicates when a significant TEER reduction was seen at particular time point
compared to the corresponding control of [3H]-octreotide alone.
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Figure 3. A. Papp of [3H]-octreotide in the absence and presence of 20 mM SNAC in KH,
rSIF, and FaSSIF-V2 in rat jejunal mucosae. *P < 0.05, one-way ANOVA followed by
Dunnett’s post hoc analysis comparing the Papp in rSIF and FaSSIF-V2 in the presence of 20
mM SNAC to that seen in KH buffer. B. Percentile of initial TEER in the controls and in the
presence of 20 mM SNAC in different buffers, *P < 0.05, two-way ANOVA followed by
Bonferroni post hoc analysis to compare reduction in TEER in tissue exposed to SNAC
35

versus the control from individual regions. Data represent Mean ± SEM (n= 3-7). The dotted
line indicates when a significant TEER reduction was seen at particular time point compared
to the corresponding control of [3H]-octreotide alone.
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Figure 4. Papp of [3H]-octreotide and unlabelled octreotide across human colonic mucosae in
the presence of SNAC in KH buffer. A. Papp of [3H]-octreotide, B. percentile of initial TEER
(with [3H]-octreotide alone used in controls), C. Papp of unlabelled octreotide, D. percentile of
initial TEER (with unlabelled octreotide alone used in controls). Mean ± SEM (n= 3-6 per
group). *P < 0.05, A: one-way ANOVA followed by Dunnett’s post hoc analysis, C:
Student’s unpaired t-test, and B and D: two-way ANOVA followed by Bonferroni post hoc
analysis to compare reduction in TEER in presence of SNAC to the control. The dotted line
indicates when a significant TEER reduction was seen at particular time point compared to
the corresponding controlof [3H]-octreotide alone.

Figure 5. Papp of [3H]-octreotide in the absence and presence of SNAC using FaSSCoF on the
apical side of human colonic mucosae. A. Papp of [3H]-octreotide and B. percentile of initial
TEER in FaSSCoF. Data is Mean ± SEM (n= 3). *P < 0.05, A: one-way ANOVA followed
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by Dunnett’s post hoc analysis, and B: two-way ANOVA followed by Bonferroni post hoc
analysis to compare reduction in TEER in presence of SNAC to the controls exposed to [3H]octreotide alone. The dotted line indicates when a significant TEER reduction was seen at
particular time point compared to the corresponding control [3H]-octreotide alone.
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Figure 6. Representative images of A. rat regional mucosae and B. human colonic stained
with H&E following exposure to SNAC in KH buffer for 120 min. Horizontal bars = 150-250
μm. (i) intact villi, (ii) erosion at tip of villi, (iii) erosion of villi and (iv) odema.
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